Navigation Links
Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
Date:2/3/2010

out Edoxaban

Edoxaban, the free base of DU-176b, is an oral anticoagulant that directly inhibits Factor Xa, an important factor in the coagulation process. Daiichi Sankyo is developing edoxaban as a potential new treatment for the prevention of both arterial and venous thromboembolism.  Notably, Daiichi Sankyo has more than 25 years experience conducting research in the area of Factor Xa inhibition, and was the first company to study these compounds in humans. Edoxaban is being developed solely by Daiichi Sankyo.

Daiichi Sankyo is also actively enrolling 16,500 patients in its pivotal Phase III trial for edoxaban in patients with atrial fibrillation. The Phase III study, Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation (ENGAGE AF-TIMI 48), began enrolling patients in late 2008 and is comparing edoxaban with warfarin (target INR 2-3) for the prevention of stroke and systemic embolic events (SEE) among patients with atrial fibrillation.

In Japan, edoxaban is currently being developed for the prevention of VTE in patients after total knee (TKR) and total hip replacement (THR) surgery: results from one pivotal Phase III trial for TKR were announced in late 2009 and a second Phase III trial for THR is ongoing.

About Daiichi Sankyo

A global pharmaceutical innovator, Daiichi Sankyo Co., Ltd., was established in 2005 through the merger of two leading Japanese pharmaceutical companies. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. Areas of central focus of Daiichi Sankyo research and development are thrombotic disorders, malignant neoplasm, diabetes mellitus and autoimmune disorders. Equally important to the company are hypertension, hyperlipidemia or atherosclerosis and bacterial
'/>"/>

SOURCE Daiichi Sankyo
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation
2. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
3. Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
4. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
5. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
8. Celsis Initiates Patent Infringement Action Against XenoTech and Sekisui
9. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
10. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
11. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... , May 20, 2013 Sequent Medical, ... for the SL ("Single Layer") family of WEB ® ... release of these new models in select neurovascular centers ... and superior navigability that will enable physicians to treat ... The SL configurations are made possible by ...
(Date:5/20/2013)... ATLANTA , May 20, 2013  Atlantic ... developed and is commercializing a unique technology to ... founder and President, Anthony Soscia ... the Atlanta Business Chronicle ,s Health-Care Heroes ... Atlanta Business Chronicle to honor individuals and ...
(Date:5/20/2013)... 20, 2013 Enrollment of patients with Type ... dose-finding clinical trial of product candidate NewMet ™, ... for Type 2 diabetes. Elcelyx expects to complete enrollment ... June. Results of the trial,s primary endpoint of change ... and the read-out for long-term glucose lowering and weight ...
Breaking Medicine Technology:Sequent Medical, Inc. Launches New SL Family of WEB Aneurysm Embolization Devices 2Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 4
... Karyopharm Therapeutics Inc., a leader in the new field of ... nuclear transport machinery plays an integral role in the regulation of ... disease. Karyopharm is focused on the discovery and development of novel ... n uclear e xport (SINE) ...
... CLEVELAND, Nov. 3, 2010 From pill-sized cameras to radioactive ... Clinic,s Top 10 Medical Innovations for 2011 showcases new techniques, ... The list of breakthrough devices and therapies was selected ... unveiled during Cleveland Clinic,s 2010 Medical Innovation Summit. ...
Cached Medicine Technology:Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders 2Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders 3Cleveland Clinic Unveils Top 10 Medical Innovations for 2011 2Cleveland Clinic Unveils Top 10 Medical Innovations for 2011 3Cleveland Clinic Unveils Top 10 Medical Innovations for 2011 4
(Date:5/20/2013)... May 20, 2013 The judge overseeing ... lawsuits has called specifically for female lawyers to be ... The Rottenstein Law Group LLP acknowledges the judge’s request, ... lawsuits by providing information on Mirena side effects ... Seibel called for the addition of some female lawyers ...
(Date:5/20/2013)... N.C. May 20, 2013 Nearly 20 percent ... the U.S. are refused for transplant due to factors ... kidney,s filtering units to the organ going too long ... being discarded, these organs could be "recycled" to help ... at Wake Forest Baptist Medical Center and colleagues, reporting ...
(Date:5/20/2013)... 20 May 2013 While Huntington,s disease (HD) ... that new disease-modifying therapies in development may slow ... HD research depends upon the identification of reliable ... therapies, and these biomarkers may eventually be used ... be especially helpful to monitor changes during the ...
(Date:5/20/2013)... May 20, 2013 Dorland Health, ... of the fourth annual Case In Point Platinum ... committed to ensuring the system is patient- and ... the innovative and creative work across the healthcare ... ensuring safe transitions of care through effective care ...
(Date:5/20/2013)... Stemedica Cell Technologies , ... manufacturing, research and development, announced today that Robert ... of Interventional Cardiology Research at the University of ... Medical Advisory Board for Stemedica’s Cardiology Division. ... divides his time between the cardiac catheterization laboratories ...
Breaking Medicine News(10 mins):Health News:Mirena IUD Lawsuit Update: Judge Calls for More Input from Female Lawyers, Notes Rottenstein Law Group LLP 2Health News:Study suggests new source of kidneys for transplant 2Health News:Leading researchers report on the elusive search for biomarkers in Huntington's disease 2Health News:Leading researchers report on the elusive search for biomarkers in Huntington's disease 3Health News:Dorland Health Announces the 2013 Case In Point Platinum Awards Winners 2Health News:Noted Cardiologist Robert Wilensky to Join Stemedica Cardiology Division Scientific & Medical Advisory Board 2Health News:Noted Cardiologist Robert Wilensky to Join Stemedica Cardiology Division Scientific & Medical Advisory Board 3
... York, NY July 12, 2009) Researchers at ... compound called NIC5-15, might be a safe and effective ... to moderate Alzheimer,s disease. The two investigators, Giulio Maria ... Phase IIA preliminary clinical findings at the Alzheimer,s Association ...
... ... for Sports Medicine ,s (AOSSM) Annual Meeting in Keystone, Colorado, (July 9-12) details the benefits ... age of 14. , ... CO (Vocus) July 12, 2009 -- More and more children are participating and getting hurt ...
... strategies should help in staying calm and moving on ... for the stress level, as many in the midst of ... not surprisingly, nearly half of the 1,791 adults polled for ... that their stress had increased in the past year. As ...
... Ill., July 11, 2009 The Natural Orifice ... joint effort of the American Society for Gastrointestinal ... and Endoscopic Surgeons (SAGES), today announced Olympus, continuing ... invasive transdisciplinary therapy known as Natural Orifice Translumenal ...
... , ROCHESTER, Minn., July 11 A new Mayo ... neurodegenerative disorders in the future. The study will be ... Disease on July 11 in Vienna. , ... framework for MRI-based differential diagnosis of three common neurodegenerative ...
... ... other North American physicians as a 2009 American Orthopaedic Society for Sports Medicine ... ... Cleveland Clinic Foundation, Director of Operating Room Management, will join three other North American ...
Cached Medicine News:Health News:Mount Sinai researchers find new Alzheimer's disease treatment promising 2Health News:Risks of Delaying ACL Reconstruction in Young Athletes May Be Too High, Study Shows 2Health News:Risks of Delaying ACL Reconstruction in Young Athletes May Be Too High, Study Shows 3Health News:How to De-Stress a Recession-Riddled Life 2Health News:How to De-Stress a Recession-Riddled Life 3Health News:NOSCAR increases NOTES research with Olympus Medical Systems Corporation grant 2Health News:Mayo Clinic Study Using Structural MRI May Help Accurately Diagnose Dementia Patients 2Health News:Renowned, Cleveland Clinic Foundation, Orthopaedic Sports Medicine Surgeon, John Bergfeld, MD, Inducted into Sports Medicine Hall of Fame 2
For the quantitative determination of aspartate aminotransferase in serum. Optimized IFCC procedure without P-5'-P. 500 IU/L at 37C linearity....
The Definitive automated slide stainer is an industry standard. The Definitive allows automated slide staining in a compact, self-contained and easy-to use package....
... is an "assembly-line worker" for routine staining ... laboratories. Programmable continuous slide stainer for routine ... slides in short time. Its large number ... continuous working principle provides a high throughput. ...
HMS 760 Robot Stainer. Version includes display....
Medicine Products: